Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,156.00
Bid: 12,124.00
Ask: 12,128.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,114.00
High: 12,258.00
Low: 12,114.00
Prev. Close: 12,170.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pay for FTSE 100 bosses jumps 16% as wider wages behind inflation

Tue, 22nd Aug 2023 06:06

(Alliance News) - The bosses of Britain's biggest companies saw their pay surge by 16% last year as most workers saw their pay packets outstripped by inflation, according to new research.

The High Pay Centre said chief executive officers for firms on the FTSE 100 – the index of the UK's largest publicly listed companies – had an average pay rise of around GBP500,000 in 2022.

Unions said the data shows that Britain has become "a land of grotesque extremes".

Median pay for a FTSE 100 CEO increased from GBP3.38 million in 2021 to GBP3.91 million in 2022, the High Pay Centre said.

It represents a continued upward trend after it dropped to GBP2.46 million in 2020 as companies were impacted by the Covid-19 pandemic.

The research shows that the gap between bosses and workers widened further over the year, with it recording that the median FTSE 100 CEO was paid 118 times the median UK full-time worker, up from 108 times in 2021.

AstraZeneca PLC boss Pascal Soriot was the highest-earning FTSE 100 chief after receiving pay of GBP15.3 million for the year.

Other particularly highly paid chief executives included Charles Woodburn of BAE Systems PLC, Bernard Looney of BP PLC and Ben van Beurden of Shell PLC.

The High Pay Centre has called for new requirements for companies to include a minimum of two elected workforce representatives on the remuneration committees that set executive pay.

Luke Hildyard, director of the think tank, said: "At a time when so many households are struggling with living costs, an economic model that prioritises a half-a-million-pound pay rise for executives who are already multi-millionaires is surely going wrong somewhere.

"How major employers distribute the wealth that their workforce creates has a big impact on people's living standards.

"We need to give workers more voice on company boards, strengthen trade union rights and enable low- and middle-income earners to get a fairer share in relation to those at the top."

It comes a week after official figures showed that average wages are continuing to grow behind rises in the cost of living.

The Office for National Statistics said regular pay growth, which excludes bonuses, reached 7.8% over the three months to June compared to a year earlier, but actually dropped by 0.6% once inflation was taken into account.

TUC general secretary Paul Nowak said: "While millions of families have seen their budgets shredded by the cost-of-living crisis, City directors have enjoyed bumper pay rises.

"This is why workers must be given seats on company boards to inject some much-needed common sense and restraint.

"We need an economy that delivers better living standards for all – not just those at the top.

"But under the Tories, Britain has become a land of grotesque extremes."

By Henry Saker-Clark, PA Deputy Business Editor

source: PA

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.